Eslicarbazepine acetate (BIA 2-093)
BIA-2093-305
Phase 3 small_molecule completed
Quick answer
Eslicarbazepine acetate (BIA 2-093) for Partial Epilepsy in Children and Adolescents is a Phase 3 program (small_molecule) at Bial Portela & Companhia S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bial Portela & Companhia S.A.
- Indication
- Partial Epilepsy in Children and Adolescents
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed